Evidence map›Paper›PMID 37941648›Full record

ArticleAmerican journal of clinical and experimental urology2023

Clear cell renal cell carcinoma with

Jennifer Lee, Moe Thuzar, Angela C DiPoto-Brahmbhatt, Catherine Chaudoir, Anthony Tanner, Tajammul Fazili, Xiuping Yu, Michael Constantinescu, Y Albert Yeh

Abstract readCase Reports
PubMed Full text at PMC
In one paragraph

Article in American journal of clinical and experimental urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. An overview of BAP1 biological functions and current therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jennifer LeePathology and Laboratory Medicine Service, Overton Brooks VA Medical Center Shreveport, LA, USA.
Moe ThuzarPathology and Laboratory Medicine Service, Overton Brooks VA Medical Center Shreveport, LA, USA.
Angela C DiPoto-BrahmbhattPathology and Laboratory Medicine Service, Overton Brooks VA Medical Center Shreveport, LA, USA.
Catherine ChaudoirPathology and Laboratory Medicine Service, Overton Brooks VA Medical Center Shreveport, LA, USA.
Anthony TannerPathology and Laboratory Medicine Service, Overton Brooks VA Medical Center Shreveport, LA, USA.
Tajammul FaziliDepartment of Urology, Overton Brooks VA Medical Center Shreveport, LA, USA.
Xiuping YuDepartment of Urology, Louisiana State University Health Shreveport Shreveport, LA, USA.
Michael ConstantinescuPathology and Laboratory Medicine Service, Overton Brooks VA Medical Center Shreveport, LA, USA.
Y Albert YehPathology and Laboratory Medicine Service, Overton Brooks VA Medical Center Shreveport, LA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell renal cell carcinoma is the most common subtype of renal cell carcinomas (RCCs) and accounts for 60%-70% of all RCCs cases in adults. Aberrations in the von Hippel-Lindau (

Indexed as

BAP1 mutationClear cell renal cell carcinomaeosinophilic granuleshyaline globules

Identifiers

PMID37941648
PMCPMC10628621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.